fortification at total fluid intake achievement of 80 or 160 ml/kg/ day (160 being standard protocol). Outcomes measured included weight, protein intake, biochemical markers, feeding intolerance and length of stay (LOS).
IS GENTAMICIN BEING APPROPRIATELY AND EFFECTIVELY ADMINISTERED TO NEONATES IN THE SPECIAL CARE NURSERY (SCN) AT THE NORTHERN HOSPITAL?
Claudia Ashkar 1* , Wei Qi Fan 1 , Ashkar C Northern Health, Melbourne, Australia Background: Gentamicin is an aminoglycoside antibiotic used to treat neonates with presumed or proven bacterial sepsis. Dose and timing in neonates is controversial owing to risks of nephrotoxicity and ototoxicity. A gentamicin trough concentration ? 2 mg/L is associated with minimal toxicity. This retrospective study aims to assess the efficacy of the current 4 mg/kg gentamicin regimen for neonates >32 weeks gestation who had presumed sepsis within the first 7 days of life.
Method: 156 neonates admitted to Special Care Nursery (February 2014 -January 2016) were identified as having had one or more serum gentamicin concentration levels analysed. Trough levels were identified and a chart review was undertaken to investigate comorbidities, patient presentation, gentamicin prescribing patterns and evidence of possible toxicity.
Results: 96% of all neonates had a safe gentamicin trough level ?2 mg/L. One neonate >37 weeks gestation (0.8%, n = 124), one neonate between 34-36 +6 weeks gestation (5.9%, n = 17) and four neonates <34 weeks gestation (26.7%, n = 15; p = 0.0004 when compared to >37 weeks cohort) had trough levels >2 mg/L. Among neonates with elevated trough levels, the current protocol was adhered to in 5 of 6 cases. Gentamicin was either ceased or dosage delayed so that subsequent trough levels were <2 mg/L. No ototoxicity was observed on follow up. Conclusions: A once daily gentamicin regimen of 4 mg/kg has resulted in few toxic trough levels in neonates >34 weeks gestation. However, younger neonates are more prone to elevated trough levels and this requires further evaluation in future gentamicin administration protocols. Royal Children's Hospital Background: Infants with duct-dependent congenital heart disease (DD-CHD) are sometimes born very preterm (<32 weeks' gestation). These infants may require prolonged infusions of PGE1 to maintain ductal patency, whilst attaining sufficient weight to undergo cardiac surgery. Literature on the outcomes of this patient group is sparse. The objective was to describe mortality and morbidity of very preterm infants with DD-CHD, treated with PGE1.
OUTCOMES OF VERY PRETERM INFANTS RECEIVING PROSTAGLANDIN (PGE1) FOR DUCT-DEPENDENT
Method: A review of medical records of very preterm infants born at the Royal Women's Hospital, Melbourne, between 2006 and 2016 with DD-CHD, treated with PGE1.
Results: 14 infants were identified, with a median (range) gestational age of 30 + 3 weeks' (26 + 4 to 31 + 6 weeks'), a median (range) birth weight 1288 g (750 g to 1660 g). 8 (57%) were male. 11 (79%) were diagnosed with DD-CHD antenatally and 12 (86%) received antenatal corticosteroids. 7 (50%) infants had duct-dependent pulmonary circulation, 5 (36%) had duct-dependent systemic circulation and 2 (14%) had transposition of the great arteries. PGE1 was commenced at a median (range) age of 0 days (0 to 12 days), with a median (range) duration of treatment of 23 days (2 to 68 days). 9 (64%) were enterally fed whilst on PGE1. 4 (29%) developed necrotising enterocolitis, with 2 requiring surgery. Mortality at discharge from tertiary centres was 29%, with 1 infant dying prior to and 3 post cardiac surgery.
Conclusions: Very preterm infants with DD-CHD have substantial morbidity and mortality. These findings are important for the treating clinicians, particularly in counselling parents of these high-risk infants.
